



# **Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016**

Weekending:- 22-03-2018

Legal Publication Date:- 13-04-2018

Journal Code (180413)



**NEW APPLICATIONS FOR THE PATENTS**

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

<b>19-03-2018</b>		
166/2018	BYUN Korea (Priority 07-04-2017 KR)	“METHOD FOR MANUFACTURING PRESSURE CONTAINER INCLUDING IN-MOLD LABEL AND THREE-DIMENSIONAL PORTION”
167/2018	SAAD BIN FARRUKH Karachi – Pakistan	“SELF-RECHARGEABLE PORTABLE COMMUNICATION DEVICE”
168/2018	Ionis Pharmaceuticals, Inc. USA (Priority 24-03-2017 US)	“MODULATORS OF PCSK9 EXPRESSION”
169/2018	CENTRE OF EXCELLENCE IN MOLUCULAR BIOLOGY Lahore – Pakistan	“A Novel Technique to Enhance Sugar Recovery in Pakistani Sugarcane”
<b>20-03-2018</b>		
170/2018	Dr. Amir Khurram Rashid Mianwali – Pakistan	“A Synthesized Sine Wave Inverter”
171/2018	FMC Corporation USA (Priority 28-03-2017 US)	“NOVEL PYRIDAZINONE HERBICIDES”
172/2018	Dr. Safia Javed Dr. Muhammad Ismail	“Sol Gel Reflux Synthesis and Characterization of TiO <sub>2</sub> Quantum

	Dr. Muhammad Mujahid Islamabad – Pakistan	Dots”
<b>21-03-2018</b>		
173/2018	Farman Ali Dr. Khalid M. Khan Dr. Shahnaz Perveen Dr. Uzma Salar Karachi Dr. Muhammad Taha Saudi Arabia	”A Process for the preparation of 4-(3-fluorophenyl)-2-(2-(1-pyridin-2-yl)ethylidene) hydrazinyl)thiazole, a potent B-glucuronidase inhibitors”
174/2018	Dr. Muhammad Athar Abbasi Lahore Dr. Khalid M. Khan Karachi Dr. Aziz-ur-Rehman Lahore Dr. Shahnaz Perveen Karachi Dr. Sabahat Zahra Siddiqui Lahore Dr. Muhammad Ashraf Bahawalpur – Pakistan	”A Process for the preparation of 2-{5-[2-amino-1,3-thiazol-4-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)-N-(2,6-dimethylphenyl) acetamide, a persuasive therapeutic agent for type 2 diabetes”
175/2018	Dr. Muhammad Ali Karachi – Pakistan	“PLACING AND LEVELING HOLDER FOR TILES”
176/2018	Dr. Muhammad Ali Karachi – Pakistan	“ELECTRICALLY CONDUCTIVE CARBON BLACK DISPERSIONS AND PRITING INKS THEREOF”
177/2018	Dr. Muhammad Ali Karachi – Pakistan	“TELESCOPIC DIVERSION/WARNING LIGHT SYSTEM FOR SERVICE VEHICLES ON ROAD”
178/2018	LOTTE CO., LTD.	“SOFT CANDY”

	Japan (Priority 27-03-2017 JP)	
179/2018	WING ACOUSTICS LIMITED NEW ZEALAND (Priority 22-03-2017 NZ)	“SYSTEM METHODS AND DEVICES RELATING TO AUDIO TRANSDUCERS, SLIM ELECTRONIC DEVICES AND HINGE SYSTEMS”
180/2018	Ludwig-Maximilians-Universitat Munchen (Priority 21-03-2017 US)	“GENE THERAPY FOR THE TREATMENT OF CNGBI-LINKED RETINITIS PIGMENTOSA”
<b>22-03-2018</b>		
181/2018	JK GROUP S.P.A. ITALY (Priority 23-03-2017 IT)	“BLACK INK”
182/2018	XEDA INTERNATIONAL S.A. FRANCE (Priority 22-03-2017 FR)	“Process for the Treatment by a Biocide or Safener Product with Average Volatility Corresponding Treatment Assembly and Storage Assembly”
183/2018	Katholieke Universiteit Leuven, Belgium Janssen Pharmaceuticals, Inc., USA (Priority 31-03-2017 EP)	“SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS”
184/2018	MEKOTEX (PVT) LIMITED, Karachi – Pakistan	“CUSTOMIZED LACE”
185/2018	XEROS LIMITED United Kingdom (Priority 24-03-2017 UK)	“Apparatus and method for treating a substrate with solid particles in a rotatably mounted drum”

186/2018	Imran Farooq Lahore Zarqa Shahid Australia	"Increasing the filtration rate of Slow Sand Filtration System"
187/2018	Novartis AG Switzerland (Priority 24-03-2017 CN)	"ISOXAZOLE CARBOXAMIDE COMPOUNDS A'ND USES THEREOF
188/2018	Novartis AG Switzerland (Priority 23-03-2017 CN)	"ANHYDROUS CRYSTALLINE FORMS OF SODIUM (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINECARBOXYLATE"

**APPLICATION ACCEPTED**

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.



The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

607/2008	BAYER Cropscience NV., Belgium.	<p>"A chimeric gene comprising a promoter gene, a DNA encoding an insecticide Cry1C protein, and a 3' polyadenylation and transcript termination region"</p> <p>C12N15/00 &amp; C12N15/82.</p> <p style="text-align: right;"><b>142722</b></p> <p>The present invention relates to novel DNA sequences encoding insecticidal Cry1C proteins derived from <i>Bacillus thuringiensis</i>, and their use in plants to control insect pests. Also included herein are plant cells or plants particularly rice plant cells or plants comprising such genes and methods of making or using them, as well as plant cells or plants comprising a Cry1C chimeric gene of the invention and at least one other chimeric gene, such as a chimeric gene encoding an insecticidal Cry1Ab protein, and methods of making or using such plant cells or plants.</p>
----------	------------------------------------	---


<p>393/2010</p>	<p><b>SANOFI-AVENTIS</b> France.</p>	<p>“HUMANIZED ANTIBODY SPECIFIC FOR THE PROTOFIBRILLAR FORM OF A- <math>\beta</math> PEPTIDE AND PHARMACEUTICAL COMPOSITION THEREOF”</p> <p>G01N33/68 &amp; A61K39/395.</p> <p style="text-align: right;"><b>142723</b></p> <p>The present invention provides a humanized antibody specific for the protofibrillar form of the A-<math>\beta</math> peptide characterized in that said antibody comprises CDRs having the sequence identical to the sequences SEQ ID NO: 10, 12, 14, 16, 18 and 20, or differs by one amino acid relative to one of the sequences SEQ ID NO: 10, 12, 14, 16, 18 and 20 and antibody of the present invention binds to the A- <math>\beta</math> peptide aggregated in senile plaques and not to the diffuse deposits of A- <math>\beta</math> peptides. The antibody of the present invention is therapeutically effective for use in the area of Alzheimer's disease.</p>
<p>470/2010</p>	<p><b>Sanofi-Aventis</b> Deutschland GmbH Germany</p>	<p>“INNER HOUSING FOR A DRUG DELIVERY DEVICE”</p> <p>A61M5/315.</p> <p style="text-align: right;"><b>142724</b></p> <p>A dose setting mechanism (4; 200) for a drug delivery device is disclosed. The mechanism comprises an outer housing (40; 204) and an inner housing (208) having an external groove. The inner housing guides a driver (30; 209) to dispense a set dose. A dial sleeve (10; 206) is disposed between the outer and inner housing and is rotatably engaged with the inner housing. When a dose is set, the dial sleeve is rotated and translates away from both the outer housing and the inner housing.</p>

		
<p>877/2010</p>	<p>NOVARTIS AG Switzerland</p>	<p>“(2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol and analogs thereof”</p> <p>A01N43/04 &amp; A61K31/70.</p> <p style="text-align: right;"><b>142725</b></p> <p>This invention relates to compounds represented by formula (I):</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.</p>



<p>203/2011</p>	<p>ImClone LLC U.S.A.</p>	<p>“AN ANTIBODY THAT BINDS HUMAN COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) WITH HIGH AFFINITY”</p> <p>C07K116/00.</p> <p style="text-align: right;"><b>142726</b></p> <p>The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.</p>
<p>392/2011</p>	<p>Akzo Nobel Coatings International B.V. Netherlands.</p>	<p>“AN AQUEOUS LIQUID COLORANT COMPOSITION HAVING LOW VOLATILE ORGANIC CONTENT”</p> <p>C09D11/00.</p> <p style="text-align: right;"><b>142727</b></p> <p>The present invention provides an aqueous liquid colorant composition having a volatile organic content up to 50g/l and suitable for colouring aqueous or solventborne architectural coatings and basepaints comprising based on the total weight of the composition,</p> <ul style="list-style-type: none"> <li>i) from 2 to 22% of non-volatile organic liquid having a vapour pressure up to 1.3 N/m<sup>2</sup> at 25°C</li> <li>ii) from 2 to 13% of stabilising agent</li> <li>iii) from 4 to 77% of colour pigment</li> <li>iv) from 0.1 to 8% of rheology modifying clay</li> <li>v) from 0 to 20% of extender</li> </ul> <p>wherein the ratio of the combined weight of iii)+iv)+v) : the combined weight of i)+ii) is from</p>


		<p>0.8 to 2.75:1 and  the combined weight of the non-volatile organic liquid i) and the stabilising agent ii) is no greater than 28% and  the combined weight of the rheology modifying clay iv) and the extender v) is at least 2% when the amount of colour pigment is less than 51%.</p>
<p>741/2011</p>	<p>VAN DEN BEMPT,  Francoise  Belgium.</p>	<p>“DEVICE FOR TREATING AND/OR TANNING SKIN AND/OR TEXTILE ELEMENTS”</p> <p>C14C15/00.</p> <p style="text-align: right;"><b>142728</b></p> <p>The present invention describes a device (10) for treating and/or tanning skins and/or textile elements comprising a rotating drum (11) having a wall of circumvolution (111) around a central rotation axis (12) and at both of its ends (113a,114) a first (113) and a second (114) side wall, the drum (11) being designed to receive the said skins and/or textile elements and at least one treatment liquid, characterized in that the said device comprises at least:</p> <ul style="list-style-type: none"> <li>- a first circuit designed to inject the said treatment liquid into the drum (11),</li> <li>- a second circuit designed to extract from the drum (11) at least part of the treatment liquid, characterized in that the first circuit comprises at least one inlet channel (131) for the treatment liquid, wherein said inlet channel comprises an external wall provided with perforations (132) and wherein said inlet channel extends essentially along the central axis (12) of the drum (11), and in that the second circuit comprises at least one outlet channel (144) for the polluted treatment liquid or waste waters, wherein said outlet channel extends along the central axis (12) of the drum (11) and wherein said outlet channel (144) is arranged inside the inlet channel (131).</li> </ul>


		
<p>798/2011</p>	<p>Laboratorios LETI, S.L. Unipersonal Spain.</p>	<p>“A NUCLEIC ACID MOLECULE OR A POLYPEPTIDE TO INCREASE AN IMMUNE RESPONSE”</p> <p>C12N15/67, C07K14/44 &amp; C07H21/02.</p> <p style="text-align: right;"><b>142729</b></p> <p>The invention relates to a new adjuvant and to its use in combination with an antigen.</p>
<p>885/2011</p>	<p>AMERICAN PACIFIC CORPORATION U.S.A.</p>	<p>“A FIRE EXTINGUISHING UNIT COMPRISING A FIRE EXTINGUISHING HYDROCHLOROFLUOROCARBON COMPOSITION”</p> <p>A62D1/02.</p> <p style="text-align: right;"><b>142730</b></p> <p>Compositions are described which are useful in many applications such as fire extinguishing or refrigeration. The compositions may include a hydrochlorofluorocarbon such as 2,2-dichloro-1,1,1-trifluoroethane, a dispersant such as CF<sub>3</sub>I, and an inert gas such as argon, and may in some</p>

		embodiments be held under pressure. For example, some fire extinguishing compositions may be composed of 2,2-dichloro-1,1,1-trifluoroethane, CF <sub>3</sub> I, and argon.
936/ 2011	SUMITOMO CHEMICAL COMPANY, LIMITED Japan.	<p>“ A PROCESS FOR PRODUCING SUSPENSION FORMULATION OF HEMIHYDRATE OF A SULFONYLUREA”</p> <p>C07D487/04.</p> <p style="text-align: right;"><b>142731</b></p> <p>The present invention provides a process for producing a suspension formulation, which comprises mixing a hemihydrate of a sulfonylurea compound represented by formula (1):</p> <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div> <p>a thickening agent, a surfactant and water.</p>
186/ 2012	Sanofi-Aventis Deutschland GmbH Germany.	<p>“ DOSE SETTING MECHANISM AND INJECTION DEVICE”</p> <p>A61M5/24.</p> <p style="text-align: right;"><b>142732</b></p> <p>A dose setting mechanism (1) for a drug delivery device is provided comprising a dose setting member (3), a drive member (4), a clutch (5a, 5b), a first clicker (6') and second clicker (6''). The first clutch (5a, 5b) and a second clutch (10, 11) are designed and adapted to each other such that at any time during operation either the first clutch (5a, 5b) rotationally couples the dose setting member (3) and the drive member (4) and/or the second clutch (10, 11) rotationally couples the drive member (4) and the first clicker component (6'). Further, the</p>


		<p>invention refers to an injection device with such a dose setting mechanism.</p>
<p>500/ 2012</p>	<p>AstraZeneca AB. Sweden.</p>	<p>“ N-(2-{2-Dimethylaminoethyl-methylamino}-4-methoxy-5- {[4-(1-methylindol-3-yl)pyrimidin-2-y]amino} phenyl)prop-2-enamide compound”</p> <p>A61K31/404,C07D401/04 &amp; C07D401/02.</p> <p style="text-align: right;"><b>142733</b></p> <p>The present invention relates to the compound N-(2-{2-Dimethylaminoethyl-methylamino}-4-methoxy-5- { [4-( 1 -methylindol-3-yl)pyrimidin-2-y]amino} phenyl)prop-2-enamide:</p> <div style="text-align: center;"> </div> <p>which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compound may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compound, especially useful polymorphic forms of these compound, intermediates useful in the manufacture of said compound and to methods of treatment of diseases mediated by various different forms of EGFR using said compound</p>

<p>754/ 2012</p>	<p>Regeneron Pharmaceuticals, Inc. U.S.A.</p>	<p><b>“AN ANTI-IL-6R ANTIBODY COMBINED WITH A VEGF ANTAGONIST FOR INHIBITING TUMOR GROWTH”</b></p> <p>C07K16/32.</p> <p style="text-align: right;"><b>142734</b></p> <p>The present invention relates to a pharmaceutical formulation comprising an IL-6 antagonist alone or in combination with a VEGF antagonist for inhibiting or attenuating tumor growth in a subject.. The formulation works particularly well on an anti-VEGF-resistant tumor. The IL-6 antagonist may be, e.g., an antibody that specifically binds IL-6R. The IL-6 antagonist may be administered in combination with a VEGF antagonist, and/or an EGFR antagonist. Improved results in terms reducing tumor growth in mice are shown by administering a combination of an anti-IL-6R mAb1 and a VEGF-trap to mice.</p> <div style="text-align: center;"> <table border="0"> <tr> <td colspan="4">A549 (Lung)</td> <td colspan="4">Calu3 (Lung)</td> <td colspan="4">Du145 (Prostate)</td> </tr> <tr> <td colspan="12"></td> </tr> <tr> <td>1.0</td><td>0.6</td><td>4.6</td><td>1.3</td> <td>1.0</td><td>0</td><td>2.3</td><td>0</td> <td>1.0</td><td>0.7</td><td>1.9</td><td>0.9</td> </tr> </table> <p>1) hFc; 2) anti-IL-6R mAb1; 3) IL-6 + hFc; 4) IL-6 + anti-IL-6R mAb1</p> </div>	A549 (Lung)				Calu3 (Lung)				Du145 (Prostate)																1.0	0.6	4.6	1.3	1.0	0	2.3	0	1.0	0.7	1.9	0.9
A549 (Lung)				Calu3 (Lung)				Du145 (Prostate)																														
1.0	0.6	4.6	1.3	1.0	0	2.3	0	1.0	0.7	1.9	0.9																											
<p>796/ 2012</p>	<p>DOW AGROSCIENCES LLC, U.S.A.</p>	<p><b>“ SYNERGISTIC HERBICIDAL COMPOSITION CONTAINING PENOX SULAM AND GLUFOSINATE-AMMONIUM”</b></p> <p>A01N43/90 &amp; A01P13/00.</p> <p style="text-align: right;"><b>142735</b></p> <p>A synergistic mixture of penoxsulam and glufosinate-ammonium controls weeds in crops, e.g., vineyards, orchards, perennial plantation crops, rice, corn, cereals, sorghum, soybeans, cotton, sunflower, oilseed rape, vegetables, turf,</p>																																				

		<p>range and pasture, industrial vegetation management (IVM), rights-of-way and in any glufosinate-ammonium and/or ALS (acetolactate synthase)-tolerant crops.</p>
<p>651/2013</p>	<p>INTERLOOP LIMITED. Pakistan.</p>	<p>“A knitted sock having a specially shaped toe with multiple gores and extra fabric length”</p> <p>D04B1/108 &amp; D04B1/26.</p> <p style="text-align: right;"><b>142736</b></p> <p>A knitted sock includes a specially shaped toe with multiple gores and extra fabric length to cover portions of a wearer's toe digits, permitting the sock to assume a relaxed form with reduction of pressure on or along a wearer's toe digits. A sock toe portion may include left and right side boundaries, a first left side gore proximate to the left side boundary, a second left side gore distanced (e.g., inset) from and non-intersecting with the first left side gore, a first right side gore proximate to the right side boundary, and a second right side gore distanced (e.g., inset) from and non-intersecting with the first right side gore</p> 

<p>111/2014</p>	<p>DOW AGROSCIENCES LLC. U.S.A.</p>	<p>“Synergistic Herbicidal Composition Comprising Penoxsulam And Acetochlor”</p> <p>A01N43/90 &amp; A01N37/26.</p> <p style="text-align: right;"><b>142737</b></p> <p>Disclosed herein are herbicidal compositions comprising a synergistic herbicidally effective amount of (a) penoxsulam or an agriculturally acceptable salt thereof and (b) acetochlor or an agriculturally acceptable salt thereof. Also disclosed herein are methods of controlling undesirable vegetation, which comprise applying to vegetation or an area adjacent the vegetation or applying to soil or water to prevent the emergence or growth of vegetation (a) penoxsulam or an agriculturally acceptable salt thereof and (b) acetochlor or an agriculturally acceptable salt thereof, wherein (a) and (b) are each added in an amount sufficient to produce a synergistic herbicidal effect.</p>
<p>165/2014</p>	<p>DOW AGROSCIENCES LLC, U.S.A.</p>	<p>“HERBICIDAL COMPOSITION COMPRISING 4-AMINO-3-CHLORO-5-FLUORO-6-(4-CHLORO-2-FLUORO-3-METHOXYPHENYL) PYRIDINE-2-CARBOXYLIC ACID”</p> <p>A01N63/00, A01N43/00, A01N43/40 &amp; A01N43/36.</p> <p style="text-align: right;"><b>142738</b></p> <p>Provided herein are herbicidal composition containing (a) a compound of formula (I):</p> <div style="text-align: center;">  <p>(I)</p> </div>



		<p>or an agriculturally acceptable salt or ester thereof and (b) insecticides, including but not limited to, acephate, carbaryl, carbofuran, cartap, chlorpyrifos, cypermethrin, dimethoate, dinotefuran, etofenprox, fenitrothion, fipronil, imidacloprid, lambda-cyhalothrin, malathion, methamidophos, piperonyl butoxide, spinetoram, spinosad, sulfoxaflor and triazophos. The compositions and methods provided herein control undesirable vegetation, e.g., in direct-seeded, water-seeded and transplanted rice, cereals, wheat, barley, oats, rye, sorghum, corn/maize, sugarcane, sunflower, oilseed rape, canola, sugar beet, soybean, cotton, pineapple, pastures, grasslands, rangelands, fallowland, turf; tree and vine orchards, plantation crops, vegetables, industrial vegetation management (IVM) and rights-of-way (ROW).</p>
<p>392/ 2014</p>	<p>AstraZeneca AB Sweden.</p>	<p>“A pharmaceutically acceptable salt of the compound: N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{{4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide”</p> <p>A61K31/04, C07D401/04 &amp; C07D401/02.</p> <p style="text-align: right;"><b>142739</b></p> <p>A pharmaceutically acceptable salt of the compound: N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{{4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide, where the structure of the compound is:</p> 

		<p>which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compound may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compound, especially useful polymorphic forms of these compound, intermediates useful in the manufacture of said compound and to methods of treatment of diseases mediated by various different forms of EGFR using said compound</p>
--	--	---

**SEALING FEES DUE-**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of **Rs.4500/-** should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

<b>Accepted No.</b>	<b>Applicant Name</b>	<b>Application No.</b>
142640	INVERSIONES S.A. China	1367/2006
142641	Voestalpine Tubulars GmbH & Co KG, Austria.	984/2009
142642	Picanol N.V. Belgium	453/2010
142643	Industrie De Nora S.p.A., Italy.	610/2012
142644	SICPA HOLDING SA, Switzerland.	733/2013
142645	AccurlC Ltd. United Kingdom	876/2013
142646	Voestalpine Tubulars GmbH & Co KG, Austria.	481/2017


**NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS**

<b>S. No.</b>	<b>Design No.</b>	<b>Title &amp; Class</b>	<b>Applicant</b>
<b><u>20/03/2018</u></b>			
1.	19226	Manhole Cover (Class-03)	Malik Brothers
<b><u>21/03/2018</u></b>			
2.	19227	Football (Class-06)	Madrigal Sports (Pvt) Ltd.
3.	19228	Goalkeeper Gloves (Class-06)	Kicker Sports
4.	19229	Football (Class-06)	Madrigal Sports (Pvt) Ltd.
5.	19230	Football (Class-06)	Madrigal Sports (Pvt) Ltd.
6.	19231	Manhole Cover (Class-03)	Golden Enterprises
<b><u>22/03/2018</u></b>			
7.	19232	Wheel Cap (Class-03)	Shakeel Plastic and Sheet Metal Works
8.	19233	Wheel Cap (Class-03)	Shakeel Plastic and Sheet Metal Works
9.	19234	Wheel Cap (Class-03)	Shakeel Plastic and Sheet Metal Works
10.	19235	Manhole Cover (Class-03)	Asif Aslam & Company
11.	19236	Mobile Phone (Class-03)	G'Five Mobile Private Limited
12.	19237	Mobile Phone (Class-03)	G'Five Mobile Private Limited
13.	19238	Mobile Phone (Class-03)	G'Five Mobile Private Limited
14.	19239	Mobile Phone (Class-03)	G'Five Mobile Private Limited

**REGISTRATION OF DESIGNS**

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
<b><u>19/03/2018</u></b>			
1.	19036	Serving Dish (Class-3)	DOVE MELAMINE WARE
2.	19037	Bowl (Class-03)	DOVE MELAMINE WARE
3.	19038	Plate (Class-03)	DOVE MELAMINE WARE
4.	19039	Plate (Class-03)	DOVE MELAMINE WARE
5.	18942	Water Cooler (Class-03)	DOVE MELAMINE WARE
6.	18837	Dental Root Extraction Screw (Class-01)	Everbest Trading Co.

  
**(Dr. Muhammad Fayyaz Ahmad)**  
 Controller of Patents  
 & Registrar of Designs  
**Ph: 99230591**